Naurex reports data for depression compound GLYX-13

Naurex Inc. (Evanston, Ill.) reported data from a Phase IIa trial to treat treatment-resistant depression showing that a single 10 mg/kg dose of IV GLYX-13 met the primary endpoint of improving Hamilt...